Recent Updates
Recently added Catalysts
NEUP Positive Sentiment

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Friday, June 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Neuphoria Therapeutics has confirmed ongoing discussions with Scancell Holdings plc regarding a potential collaboration. This engagement suggests a strategic move to enhance their development initiatives. The talks indicate a positive outlook for Neuphoria as it seeks to expand its operational capabilities.
Price reaction · baseline $4.57 (2026-06-26 close) · hit after-hours · clean, no other NEUP news in the window
day 0 close · peak
-3.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Neuphoria is engaging in talks with Scancell Holdings.
  • The potential collaboration could enhance development efforts.
  • Neuphoria is positioned as a clinical-stage biotechnology company.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~14 mo
Low dilution risk
Lead asset
BNC105P
Phase 1 · Renal Cell Carcinoma

Full Press Release Details

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing

Frequently Asked Questions

What is the purpose of Neuphoria's talks with Scancell?

Neuphoria is discussing a potential collaboration with Scancell Holdings.

What stage is Neuphoria Therapeutics in?

Neuphoria is a clinical-stage biotechnology company.

ShareAdd on Google
Tags: NEUP Viatris Investor Conferences Healthcare Neuphoria Scancell Holdings biotechnology clinical-stage collaboration
Last updated: Jun 26, 2026

Biotech snapshot

Cash runway
$19M liquidity · $1M/mo burn
~14 mo
Low dilution risk
Lead asset
BNC105PPhase 1
Renal Cell Carcinoma →